AMO announces expansion of refractive portfolio

Article

AMO today announced the introduction of three new refractive technologies to the European market; the Tecnis 1-piece intraocular lens (IOL), the Tecnis multifocal acrylic IOL and the WhiteStar Signature phaco system.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
An image of Plaza de Espana Square in Seville, Spain. Seville is home to the 2025 Congress on Controversies in Ophthalmology. Image credit: ©Anibal Trejo – stock.adobe.com

Surgical, medical and next-generation retina topics at COPHy

Hattie Hayes
April 4th 2025
Article

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A screenshot of the United States Food and Drug Administration (FDA) web page. US FDA Complete Response Letter CRL concept. Image credit: ©Jarretera – stock.adobe.com

US FDA issues second Complete Response Letter for dry eye drug reproxalap (Aldeyra Therapeutics)

Martin David Harp
April 3rd 2025
Article

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO
April 2nd 2025
Article

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

Hattie Hayes
April 1st 2025
Article

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

© 2025 MJH Life Sciences

All rights reserved.